Preclinical testing of an anti-erbB-2 recombinant toxin

Breast Cancer Research and Treatment

Volumn 38, Issue 1, 1996, Pages 19-25

  King, C Richter ^a,b,c   Kasprzyk, Philip G ^a,b   Fischer, Paul H ^a,b   Bird, Robert E ^a,b   Turner, Nancy A ^a,b  

^a Oncologix Inc   (United States)

^b Argonex Pharmaceuticals Inc   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

erbB 2; Pharmacokinetics; Recombinant immunotoxins; Toxicity

Indexed keywords

IMMUNOTOXIN; ONCOPROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER MODEL; CONFERENCE PAPER; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; MONKEY; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; ANTIBODIES; EXOTOXINS; HUMANS; IMMUNOTOXINS; NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0030031901     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01803780     Document Type: Conference Paper

References (17)

1. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB related gene in a human mammary carcinoma. Science 229:974-976, 1985
2. Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501, 1985
3. Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230, 1986
4. Kraus MH, Popescu NC, Amsbaugh C, King CR: Overexpression of the EGF receptor-related protooncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6:605-610, 1987
5. Schneider PM, Hung M-C, Chiocca SM, Manning J, Zhao XY, Fang K, Roth JA: Differential expression of the erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49:4968-4971, 1989
6. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the c-erbB-2 gene: A 185 kd phosphoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
7. DiFiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 is a potent oncogene when overexpresscd in NIH/3T3 cells. Science 237: 178-182, 1986
8. Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p 185 (HER2) causes transformation and tumorigenesis of NIH/3T3 cells. Proc Natl Acad Sci USA 84:7159-7163, 1987
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707-712, 1989
11. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Grover B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast cancer with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1988
12. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathological findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
13. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184-5191, 1990
14. Pastan I, FitzGerald DJP: Recombinant toxins for cancer treatment. Science 254:1173-1177, 1991
15. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M: Single chain antigen binding proteins. Science 242:423-426, 1988
16. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR: Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 89:5867-5871, 1992
17. Kasprzyk PG, Song SV, DiFiore PP, King CR: Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Research 51:2771-2776, 1992